ArticleProceedings of the National Academy of Sciences of the United States of America2011

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Jianda Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.